FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166989721> ?p ?o ?g. }

• W2166989721 endingPage "399" @default.
• W2166989721 startingPage "390" @default.
• W2166989721 abstract "OBJECTIVES: To study the effect of 12 months of growth hormone (GH) treatment on bone markers, bone mineral density (BMD), lean body mass (LBM) and body fat mass (BF) in postmenopausal osteoporotic women. DESIGN: Sixteen patients were randomised to a double-blind randomised placebo-controlled one-year study with daily s.c. injections of GH or placebo. After the first year 14 patients (8 placebo treated, 6 GH treated) were recruited to GH treatment during the second year. All patients were also supplemented with 0.5 g calcium per oral. METHODS: Bone mineral density and body composition were assessed by dual energy X-ray absorptiometry. Biochemical bone markers were analysed by RIA or HPLC techniques. Diurnal GH profiles were performed with continuous venous blood sampling. RESULTS: Sixteen patients started in the placebo-controlled study. In all, twelve patients completed one year and only four patients completed two years of GH treatment. At baseline 3 patients had serum insulin-like growth factor-I (S-IGF-I) levels below -2 S.D. for age. Maximal diurnal GH levels tended to correlate negatively with S-IGF-I (P=0.076). S-IGF-I was unrelated to BMD. Serum IGF-binding protein-1 (S-IGFBP-1) correlated negatively with femoral neck BMD (r=-0.61, P=0.012). The intended GH dose of 0.05U/kg/day or a maximum of 3U/day s.c. was reduced to 0.024+/-0.004U/kg/day, equal to 0.5-2.7U/day due to frequent side effects, and four patients were excluded. After one year of GH treatment BF increased slightly, LBM and BMD in total body and lumbar spine were unchanged but femoral neck BMD had decreased 3.4+/-1.6% (P<0.05). The mean S-IGF-I increase was 32% (range -38-138%). Mean levels of the bone formation markers S-osteocalcin and S-procollagen type I propeptide increased maximally by 88 and 36% respectively after 9-12 months while the bone resorption markers were unchanged. In the placebo-treated group there were no significant alterations. CONCLUSIONS: The effects on S-IGF-I, bone markers and LBM were small although GH-related side effects were common. The reason for this apparent partial resistance to the anabolic effects of GH is not clear but nutritional deficits may be involved. Assessment of the effects of GH on bone mass and fracture rate requires longer study periods than one year." @default.
• W2166989721 created "2016-06-24" @default.
• W2166989721 creator A5000692597 @default.
• W2166989721 creator A5009597244 @default.
• W2166989721 creator A5073802207 @default.
• W2166989721 creator A5081892371 @default.
• W2166989721 creator A5081939530 @default.
• W2166989721 date "1999-05-01" @default.
• W2166989721 modified "2023-10-01" @default.
• W2166989721 title "Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study" @default.
• W2166989721 cites W1965897913 @default.
• W2166989721 cites W1968552449 @default.
• W2166989721 cites W1978228587 @default.
• W2166989721 cites W1978439674 @default.
• W2166989721 cites W1985019823 @default.
• W2166989721 cites W1987447544 @default.
• W2166989721 cites W1989657845 @default.
• W2166989721 cites W1998569023 @default.
• W2166989721 cites W1999939002 @default.
• W2166989721 cites W2015402497 @default.
• W2166989721 cites W2017945794 @default.
• W2166989721 cites W2024985730 @default.
• W2166989721 cites W2030378687 @default.
• W2166989721 cites W2041188302 @default.
• W2166989721 cites W2041203073 @default.
• W2166989721 cites W2050386090 @default.
• W2166989721 cites W2052515706 @default.
• W2166989721 cites W2054548024 @default.
• W2166989721 cites W2054654084 @default.
• W2166989721 cites W2073044609 @default.
• W2166989721 cites W2073142272 @default.
• W2166989721 cites W2079333525 @default.
• W2166989721 cites W2084239308 @default.
• W2166989721 cites W2086651817 @default.
• W2166989721 cites W2088278398 @default.
• W2166989721 cites W2094162752 @default.
• W2166989721 cites W2094741615 @default.
• W2166989721 cites W2105735751 @default.
• W2166989721 cites W2106632157 @default.
• W2166989721 cites W2121183857 @default.
• W2166989721 cites W2130909595 @default.
• W2166989721 cites W2148688487 @default.
• W2166989721 cites W2153868160 @default.
• W2166989721 cites W2153909093 @default.
• W2166989721 cites W2160588197 @default.
• W2166989721 cites W2161763667 @default.
• W2166989721 cites W2315987042 @default.
• W2166989721 cites W2485917484 @default.
• W2166989721 doi "https://doi.org/10.1530/eje.0.1400390" @default.
• W2166989721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10229902" @default.
• W2166989721 hasPublicationYear "1999" @default.
• W2166989721 type Work @default.
• W2166989721 sameAs 2166989721 @default.
• W2166989721 citedByCount "31" @default.
• W2166989721 countsByYear W21669897212014 @default.
• W2166989721 countsByYear W21669897212016 @default.
• W2166989721 countsByYear W21669897212017 @default.
• W2166989721 countsByYear W21669897212018 @default.
• W2166989721 countsByYear W21669897212019 @default.
• W2166989721 countsByYear W21669897212021 @default.
• W2166989721 countsByYear W21669897212022 @default.
• W2166989721 crossrefType "journal-article" @default.
• W2166989721 hasAuthorship W2166989721A5000692597 @default.
• W2166989721 hasAuthorship W2166989721A5009597244 @default.
• W2166989721 hasAuthorship W2166989721A5073802207 @default.
• W2166989721 hasAuthorship W2166989721A5081892371 @default.
• W2166989721 hasAuthorship W2166989721A5081939530 @default.
• W2166989721 hasBestOaLocation W21669897211 @default.
• W2166989721 hasConcept C120863210 @default.
• W2166989721 hasConcept C126322002 @default.
• W2166989721 hasConcept C134018914 @default.
• W2166989721 hasConcept C142724271 @default.
• W2166989721 hasConcept C147583825 @default.
• W2166989721 hasConcept C170033053 @default.
• W2166989721 hasConcept C170493617 @default.
• W2166989721 hasConcept C202061045 @default.
• W2166989721 hasConcept C204787440 @default.
• W2166989721 hasConcept C27081682 @default.
• W2166989721 hasConcept C2775854910 @default.
• W2166989721 hasConcept C2775960820 @default.
• W2166989721 hasConcept C2776541429 @default.
• W2166989721 hasConcept C2776886416 @default.
• W2166989721 hasConcept C2779329777 @default.
• W2166989721 hasConcept C2780689927 @default.
• W2166989721 hasConcept C2991744798 @default.
• W2166989721 hasConcept C71924100 @default.
• W2166989721 hasConceptScore W2166989721C120863210 @default.
• W2166989721 hasConceptScore W2166989721C126322002 @default.
• W2166989721 hasConceptScore W2166989721C134018914 @default.
• W2166989721 hasConceptScore W2166989721C142724271 @default.
• W2166989721 hasConceptScore W2166989721C147583825 @default.
• W2166989721 hasConceptScore W2166989721C170033053 @default.
• W2166989721 hasConceptScore W2166989721C170493617 @default.
• W2166989721 hasConceptScore W2166989721C202061045 @default.
• W2166989721 hasConceptScore W2166989721C204787440 @default.
• W2166989721 hasConceptScore W2166989721C27081682 @default.
• W2166989721 hasConceptScore W2166989721C2775854910 @default.
• W2166989721 hasConceptScore W2166989721C2775960820 @default.

• next